Search
forLearn
5 / 801 resultslearn Epidermal Growth Factor
learn Vascular Endothelial Growth Factor
learn Ethynylestradiol
learn Ethinylestradiol
Research
5 / 1000+ resultsresearch Rare Case of Alopecia: Alopecia Neoplastica
A rare case of hair loss was linked to breast cancer spreading to the scalp, but treatment was effective.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature
Kalya Research is an AI tool that effectively finds and analyzes alternative medicine literature, saving researchers time.
Community Join
5 / 1000+ resultscommunity Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community So Pyrilutamide has been postponed by one year. How likely is that to happen to GT20029
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.